Last reviewed · How we verify
NCT05471622: SHEPHERD
Study of Home-Embedded Palliative Care for Hemodialysis-Dependent End-Stage Renal Disease
NA trial testing Nudge for PHPC Referral in End-Stage Renal Disease in 285 participants. Completed in 18 December 2023.
18 June 2023
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 285 |
| Start date | 21 July 2022 |
| Primary completion | 18 June 2023 |
| Estimated completion | 18 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Nudge for PHPC Referral
Conditions studied
- End-Stage Renal Disease — all drugs for End-Stage Renal Disease →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with End-Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Home palliative care needs are often under-recognized in patients with End-Stage Renal Disease (ESRD). This pilot study is designed to evaluate the feasibility and acceptability of an initiative to enhance referrals to Penn Home Palliative Care compared with usual care among hemodialysis-dependent ESRD patients admitted to a Penn hospital. Results will inform a future pragmatic trial comparing the effectiveness of home palliative care compared with usual care among ESRD patients. Evaluating the effectiveness of home palliative care services is critical to determine whether increasing access to these services would improve patient-centered outcomes for these high-need patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05471622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End-Stage Renal Disease
Currently open trials in the same condition.
- NCT07348237 — A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) · Phase 1 · recruiting
- NCT06982573 — The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients With ESRD · NA · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT06224140 — Heparin-Free Chronic HemoDialysis Assessment · NA · recruiting
- NCT05931276 — CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes · Phase 3 · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05471622 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 21 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05471622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing